Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials
Diabetes Care · 2024
DOI: 10.2337/dc23-2366 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2024. Verfasst von Francesco Giorgino und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Uni…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Blood Glucose, Hypoglycemic Agents, Insulin, Long-Acting. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE This post hoc analysis assessed change from baseline to week 52 in glycemic parameters for tirzepatide (5, 10, 15 mg) versus insulin degludec (SURPASS-3 trial) and glargine (SURPASS-4 trial) in people with type 2 diabetes and different baseline glycemic patterns, based on fasting serum glucose (FSG) and postprandial glucose (PPG) values. RESEARCH DESIGN AND METHODS Participant subgroups with low FSG/low PPG, low FSG/high PPG, high FSG/low PPG, and high FSG/high PPG were defined according to the median values of these measures. RESULTS All tirzepatide doses and basal insulins were associated with decreased HbA1c, FSG, and PPG values from baseline to week 52 in all subgroups (P < 0.05). Within each subgroup, HbA1c and PPG decreases were greater with tirzepatide than insulin (P < 0.05). FSG decreases were generally similar. There were no differential treatment effects by FSG/PPG subgroup. CONCLUSIONS In this post hoc analysis, tirzepatide was associated with superior glycemic control compared with insulin, irrespective of baseline glycemic pattern.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.
- CPCLIN/DASA Clinical Research Center, São Paulo, Brazil.
- Eli Lilly and Company, Indianapolis, IN.
ORCID-Profile: Francesco Giorgino, Andrea Hemmingway, Ángel Rodríguez
Förderung
- Eli Lilly and Company
Zitieren
APA
Giorgino, F., Franco, D. R., Nicolay, C., Hemmingway, A., Rodríguez, Á., & Wiese, R. J. (2024). Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials. Diabetes Care. https://doi.org/10.2337/dc23-2366
Vancouver
Giorgino F, Franco DR, Nicolay C, Hemmingway A, Rodríguez Á, Wiese RJ. Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials. Diabetes Care. 2024. doi:10.2337/dc23-2366
BibTeX
@article{Giorgino2024,
author = {Giorgino, Francesco and Franco, Denise R and Nicolay, Claudia and Hemmingway, Andrea and Rodríguez, Ángel and Wiese, Russell J},
title = {Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials},
journal = {Diabetes Care},
year = {2024},
doi = {10.2337/dc23-2366}
}
EUVIMED